Completed PHASE2 INTERVENTIONAL 1-arm NCT00180674

Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Anticoagulation for Liver Fibrosis in Patients With Hepatitis C Virus Infection: Pilot Study

Sponsor: Imperial College London

Interventions Warfarin

Updated 6 times since 2017 Last updated: Nov 6, 2020 Started: Aug 31, 2005 Primary completion: Sep 30, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00180674, this PHASE2 trial focuses on Liver Fibrosis and remains completed. Sponsored by Imperial College London, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2019 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom